Related Experiment Video

Updated: Aug 15, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Bcl-2 targeting siRNA expressed by a T7 vector system inhibits human tumor cell growth in vitro

Lori Holle1, Labri Hicks, Wendy Song

  • 1Oncology Research Institute of the Greenville Hospital System, Greenville, SC 29605, USA.

International Journal of Oncology
|February 10, 2004
PubMed

Insights

A novel vector system effectively delivered Bcl-2 siRNA into breast cancer cells, reducing cancer cell proliferation and increasing apoptosis. This approach shows promise for future cancer gene therapy strategies targeting Bcl-2.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Gene Therapy

Background:

  • Bcl-2 protein is frequently overexpressed in various cancers, promoting cell survival.
  • Targeting Bcl-2 mRNA offers a potential strategy to inhibit cancer cell proliferation.

Purpose of the Study:

  • To design and validate a T7 promoter-driven siRNA expression vector system (Bcl-2/T7) for targeting Bcl-2 mRNA in human breast cancer cells (MCF-7).
  • To assess the efficacy of Bcl-2/T7 in reducing Bcl-2 expression, inhibiting cell proliferation, and inducing apoptosis in MCF-7 cells.

Main Methods:

  • Development of a T7 promoter-driven siRNA expression vector (Bcl-2/T7).
  • Transfection of MCF-7 human breast cancer cells with the Bcl-2/T7 vector.
  • Assessment of Bcl-2 siRNA expression and function using cell proliferation assays, Bcl-2 ELISA, and TUNEL assay.

Main Results:

  • Successful expression and function of Bcl-2 siRNA were demonstrated in MCF-7 cells.
  • Transfection with Bcl-2/T7 led to decreased Bcl-2 protein levels and reduced cell proliferation.
  • An increased number of apoptotic cells were observed in cells expressing Bcl-2 siRNA.

Conclusions:

  • The Bcl-2/T7 system effectively produces functional Bcl-2 siRNA in breast cancer cells.
  • This vector system has potential applications in cancer gene therapy by targeting Bcl-2.
  • Further research may explore the therapeutic potential of this delivery system for Bcl-2-overexpressing cancers.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.